Lupin gets FDA OK for generic Bactrim

Patients seeking to treat and prevent a variety of bacterial infections, such as middle ear, urine, respiratory, and intestinal infections, and certain type of pneumonia such as pneumocystis will soon have a new generic treatment.

The Food and Drug Administration has given Lupin the green light for sulfamethoxazole and trimethoprim oral suspension in a dosage strength of 200 mg/40 mg per 5 ml.

The medication is the generic of Sun Pharmaceutical’s Bactrim oral suspension.

Sulfamethoxazole and trimethoprim oral suspension has a market value of approximately $19 million, according to Lupin.